Plain-English translation of NCT05266417 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a nasal spray containing insulin (Novolin R) and glutathione—two substances your body naturally uses—can help improve symptoms in people with Parkinson's disease when used alongside their regular medications. About 56 people will participate, with some receiving the active treatment and others receiving a placebo (a dummy spray with no medicine) to see if the medication truly works. The study is designed to measure both safety and whether the treatment actually makes a difference.
Parkinson's disease affects how the brain controls movement and can worsen over time, even with current medications. Researchers believe this medication might offer additional benefit by protecting brain cells and reducing inflammation, potentially slowing symptom progression or improving quality of life.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will be randomly assigned to receive either the active nasal spray or a placebo spray. You'll use your assigned spray regularly as instructed—either on your own or with help from a caregiver—while continuing your regular Parkinson's medications unchanged. The study will involve screening visits to confirm you're eligible, regular follow-up appointments to check how you're doing, and assessments to measure any changes in your symptoms and overall safety.
AI-generated summary from trial data · Aug 1, 2026 · Not medical advice
United States